Background: IL-3, IL-5, and GM-CSF are not able to induce histamine release
in purified basophils of nonallergic donors. However, He have recently fou
nd that preincubation Kith 2 mu mol/L thapsigargin, which induces a rise in
intracellular free calcium ions, renders human basophils extremely sensiti
ve for IL-3, 1L-5, or GM-CSF, leading to enhanced histamine release. Histam
ine release was also induced in the reverse order (first cytokine and then
thapsigargin).
Objective: Because these cytokines are supposed to be increased in allergic
inflammation, we examined whether basophils of patients with allergic asth
ma showed an enhanced response to thapsigargin.
Methods: We measured the histamine release induced by thapsigargin in a gro
up of allergic asthmatic subjects (n = 24) and compared this response with
those of 3 control groups. The control groups consisted of healthy control
subjects (group 1, n = 21); patients with a nonallergic, nonasthmatic lung
disease (group 2, n = 22); and patients with nonallergic asthma (group 3, n
= 9).
Results: There was no difference in spontaneous histamine release. Also, no
significant difference in histamine release nas found when anti-IgE or for
myl-methionyl-leucyl-phenylalanine was used as a stimulus, Histamine releas
e induced by IL-3 alone or a combination of IL-3 and thapsigargin also did
not differ. In contrast, basophils from the group with allergic asthma show
ed a significantly higher percentage of histamine release induced by thapsi
gargin (38.2% +/- 13.2%) than did basophils from the 3 control groups (heal
thy control subjects, 22.5% +/- 6.9%; subjects Kith Lung disease, 24.9% +/-
8.9%;subjects dth nonallergic asthma 15.0% +/- 3.0%; all mean +/- SD).
Conclusion: These data indicate that basophils in peripheral blood of subje
cts dth allergic asthma have a primed phenotype and that thapsigargin-induc
ed histamine release is a practical tool to study this phenomenon.